Cannara BiotechLOVFF +1.87%85 3-Year ROIIC % is 36.29 as of Aug. 2025, which is 51% above its 10-year median of 24.03. GuruFocus rates LOVFF with a GF Score™ of 85/100 and a GF Value™ of $1.17 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 944 Drug Manufacturers companies, Cannara Biotech ranks better than 79.34% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Cannara Biotech's 3-Year ROIIC % for the quarter that ended in Aug. 2025 was 36.29%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Cannara Biotech's 3-Year ROIIC % or its related term are showing as below:
LOVFF's 3-Year ROIIC % is ranked better than 79.34% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs LOVFF: 36.29
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Cannara Biotech 3-Year ROIIC % Related Terms
Cannara Biotech 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Cannara Biotech's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cannara Biotech's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cannara Biotech 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cannara Biotech's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Cannara Biotech's 3-Year ROIIC % falls into.
Cannara Biotech's 3-Year ROIIC % for the quarter that ended in Aug. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( 11.4033506 (Aug. 2025) - 3.852 (Aug. 2022) )
/
( 96.774 (Aug. 2025) - 80.416 (Aug. 2022) )
=
7.5513506
/
16.358
=
46.16%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Cannara Biotech (LOVFF) has a 3-Year ROIIC % of 36.29 as of Aug. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cannara Biotech and its competitors. This is 51% above median its historical median of 24.03. Over the past decade, Cannara Biotech's 3-Year ROIIC % has ranged from 4.10 to 36.29. According to the industry distribution chart, Cannara Biotech ranks #195 out of 944 companies in the Drug Manufacturers industry, placing it in the top 20.7%.
Is Cannara Biotech's 3-Year ROIIC % too high?
Cannara Biotech's current 3-Year ROIIC % of 36.29 is 51% above median its 10-year median of 24.03. Over the past 10 years, this metric has ranged from a low of 4.10 to a high of 36.29. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Cannara Biotech's value of 36.29 is 898.3% above this industry median. Based on the distribution chart, Cannara Biotech ranks #195 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Cannara Biotech has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cannara Biotech's 3-Year ROIIC % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Cannara Biotech ranks #195 out of 944 companies for 3-Year ROIIC %. This places Cannara Biotech in the top 21% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Cannara Biotech's value of 36.29 is 898.3% above this benchmark. Historically, Cannara Biotech's own 3-Year ROIIC % has ranged from 4.10 to 36.29 over the past decade. While the company's 10-year median is 24.03 vs. the industry median of 3.64, Cannara Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cannara Biotech's current 3-Year ROIIC % of 36.29 is 898.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Cannara Biotech and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cannara Biotech's current 3-Year ROIIC % is 36.29, which is 51% above median its own 10-year median of 24.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cannara Biotech stock overvalued right now?
Based on GuruFocus' analysis, Cannara Biotech (LOVFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $1.17, compared to a current price of $1.31 — trading 12% above its estimated fair value. The current 3-Year ROIIC % is 36.29, which is 51% above median its 10-year median of 24.03 and 898.3% above the Drug Manufacturers industry median of 3.64. Cannara Biotech's overall GF Score™ is 85/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Cannara Biotech (LOVFF), the current 3-Year ROIIC % is 36.29 as of Aug. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cannara Biotech (LOVFF) Overvalued in 2026?
Based on GuruFocus' analysis, Cannara Biotech stock appears to be overvalued.
The current stock price of $1.31 is trading 12% above its estimated GF Value™ of $1.17.
GuruFocus considers Cannara Biotech to be Modestly Overvalued.
Key valuation signals for LOVFF:
3-Year ROIIC %: 36.29 (51% above median its 10-year median of 24.03)
GF Value™: $1.17 vs. price of $1.31 (12% above fair value)
Industry Position: 898.3% above the Drug Manufacturers median (#195 of 944)
No single metric tells the full story. See the LOVFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cannara Biotech Inc is a vertically integrated producer of premium-grade cannabis and cannabis-derivative products for Canadian markets. The company owns two mega Quebec-based facilities. The company operates in in two segments; Indoor cannabis operations segment which includes the cultivation, processing and sale of dried cannabis and cannabis derivatives for the Canadian market and the Real estate operations segment related to the Farnham and Valleyfield building. Majority of the revenue for the company is generated from its Cannabis operations segment. .
85GF Score
Get the complete analysis for LOVFF
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LOVFF has been successfully added to your 
